CN110244051A - A kind of multicomponent Labeled immunoassay system for diabetes - Google Patents
A kind of multicomponent Labeled immunoassay system for diabetes Download PDFInfo
- Publication number
- CN110244051A CN110244051A CN201910606263.XA CN201910606263A CN110244051A CN 110244051 A CN110244051 A CN 110244051A CN 201910606263 A CN201910606263 A CN 201910606263A CN 110244051 A CN110244051 A CN 110244051A
- Authority
- CN
- China
- Prior art keywords
- detection
- pipeline
- antigen
- multicomponent
- adsorption layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Abstract
The invention discloses a kind of multicomponent Labeled immunoassay systems for diabetes, including detection pipeline and electromagnet, the left side for detecting pipeline is respectively arranged with electromagnet up and down, electromagnet includes upper electromagnet and lower electromagnet, the left side central portion of detection pipeline is provided with separating mechanism, the left side of separating mechanism is capture chamber, the right side of separating mechanism is sensing chamber, the lower inside for detecting the right side of pipeline has been set gradually from left to right the first detection adsorption layer, second detection adsorption layer and third detect adsorption layer, the lower right-hand side of detection pipeline is provided with exciting bank, it detects and is provided with acquisition equipment above the right side of pipeline, acquisition equipment is connected by conducting wire with display device, the reagent of detection diabetes autoantibody is provided in detection pipeline；The present invention, which has the advantages that quantify, quickly to be detected, is stable.
Description
Technical field
The invention belongs to diabetes diagnosis fields, and in particular to a kind of multicomponent Labeled immunoassay system for diabetes
System.
Background technique
Diabetes are as the third-largest non-communicable diseases at present after cardiovascular disease and tumour, it has also become serious prestige
The worldwide public health problem for coercing human health, in current existing detection architecture, the diagnosis of single autoantibody detection
Meaning all has certain limitation, causes patient to be not easy to be diagnosed in diabetes early stage, to delay the treatment of early stage；
To solve the above problems, develop it is a kind of with quantitatively quickly, the stable multicomponent Labeled immunoassay for diabetes of detection
System is necessary.
Summary of the invention
The purpose of the invention is to overcome the deficiencies in the prior art, and providing one kind has quantitative quick, detection stabilization
The multicomponent Labeled immunoassay system for diabetes.
The object of the present invention is achieved like this: a kind of multicomponent Labeled immunoassay system for diabetes, including
Pipeline and electromagnet are detected, the left side for detecting pipeline is respectively arranged with electromagnet up and down, and electromagnet includes upper electromagnet and lower electricity
Magnet, the left side central portion for detecting pipeline are provided with separating mechanism, and the left side of separating mechanism is capture chamber, and the right side of separating mechanism is
Sensing chamber, the lower inside for detecting the right side of pipeline have been set gradually from left to right the first detection adsorption layer, the second detection absorption
Layer and third detect adsorption layer, and the lower right-hand side for detecting pipeline is provided with exciting bank, detect and are provided with above the right side of pipeline
Acquisition equipment, acquisition equipment are connected by conducting wire with display device, are detected in pipeline and are provided with detection diabetes autoantibody
Reagent.
Further, separating mechanism is inserted sheet.
Further, it is characterised in that: exciting bank and acquisition equipment use photomultiplier tube.
Further, there are magnetic particle, biotinylation the capture antigen, acridinium ester of Streptavidin in reagent comprising coupling
The detection antigen and substrate exciting liquid of label.
Further, the first detection adsorption layer, the second detection adsorption layer and third detection adsorption layer are respectively used to capture chain
Magnetic particle, the biotinylation of mould Avidin capture the detection antigen of antigen, acridinium ester label.
Further, the partial size of the magnetic particle of Streptavidin is 0.5-1.5 μm.
Further, biotin capture antigen selects pancreatic island cell antigen albumen, and antigen protein concentration is 0.6 μ g/ml.
Further, the detection antigen of acridinium ester label selects acridinium ester label islet cell protein, and antigen protein is dense
Degree is 3 μ g/ml.
By adopting the above-described technical solution, the beneficial effects of the present invention are:
(1) by the magnetic particle of Streptavidin of setting, biotinylation capture antigen, acridinium ester label detection antigen and
Substrate exciting liquid and the first detection adsorption layer, the second detection adsorption layer and third detect adsorption layer, quantify to diabetes
Multicomponent mark screening, improve the stability of diagnosis, prevent mistaken diagnosis, meanwhile, for Rapid&Early diagnosis go out diabetes provide according to
According to convenient for the early treatment of patient；
(2) by the first detection adsorption layer, the second detection adsorption layer and the third of setting detect adsorption layer and exciting bank,
Acquisition equipment and display device make patient understand degree locating for disease convenient for save to diagnostic data and comparing analysis.
Detailed description of the invention
Fig. 1 is schematic diagram 1 of the invention；
Fig. 2 is schematic diagram 2 of the invention.
In figure: 1, detecting pipeline 11, separating mechanism 12, first detects adsorption layer 13, second and detects adsorption layer
14, third detects adsorption layer 2, electromagnet 21, upper electromagnet 22, lower electromagnet 3, exciting bank 4, acquisition equipment
5, display device 6, reagent 7, magnetic particle 8, biotinylation capture the detection antigen of antigen 9, acridinium ester label
101, capture chamber 102, sensing chamber.
Specific embodiment
Below with reference to the embodiments and with reference to the accompanying drawing technical solution of the present invention is described in further detail.
As illustrated in fig. 1 and 2, a kind of multicomponent Labeled immunoassay system for diabetes, including detection pipeline 1 and electricity
Magnet 2, the left side for detecting pipeline 1 are respectively arranged with electromagnet 2 up and down, and electromagnet 2 includes upper electromagnet 21 and lower electromagnet 22,
Lower electromagnet 22 can be moved left and right along detection pipeline 1；The left side central portion of detection pipeline 1 is provided with separating mechanism 11, separating mechanism
11 left side is capture chamber 101, and the right side of separating mechanism 11 is sensing chamber 102, and separating mechanism 11 is inserted sheet, and separating mechanism 11 can
Insertion as needed, main function is that capture chamber 101 is isolated with sensing chamber 102；Detect the lower inside on the right side of pipeline 1
It has been set gradually from left to right the first detection adsorption layer 12, second detection adsorption layer 13 and third detection adsorption layer 14, detection pipe
The lower right-hand side in road 1 is provided with exciting bank 3, detects and is provided with acquisition equipment 4 above the right side of pipeline 1, acquisition equipment 4 passes through
Conducting wire is connected with display device 5, and exciting bank 3 and acquisition equipment 4 use photomultiplier tube, and photomultiplier tube is existing skill
Art does not describe excessively herein；It is provided with the reagent 6 of detection diabetes autoantibody in detection pipeline 1, includes even in reagent 6
It is associated with magnetic particle 7, biotinylation capture antigen 8, the detection antigen 9 of acridinium ester label and the substrate excitation of Streptavidin
Liquid, the first detection adsorption layer 12, second detects adsorption layer 13 and third detection adsorption layer 14 is respectively used to capture Streptavidin
Magnetic particle 7, biotinylation capture antigen 8, acridinium ester label detection antigen 9, the grain of the magnetic particle 7 of Streptavidin
Diameter is 0.5-1.5 μm, and biotin captures antigen 8 and selects pancreatic island cell antigen albumen, and antigen protein concentration is 0.6 μ g/ml, a word used for translation
The detection antigen 9 of pyridine ester label selects acridinium ester label islet cell protein, and antigen protein concentration is 3 μ g/ml.
In the use of the present invention, firstly, pre-processed to reagent 6, and unbonded biotinylated antibody is washed away, and
Make reagent 6 under the action of electromagnet 2, engage different determined antigens with magnetic particle respectively, at this point, separating mechanism 11
It will test pipeline 1 and be divided into capture chamber 101 and sensing chamber 102；Then, separating mechanism 11 is opened, in the left and right of lower electromagnet 22
Under the action of movement, the magnetic particle 7 of Streptavidin, biotinylation is made to capture the detection antigen 9 of antigen 8, acridinium ester label
Adsorption layer 13 is detected with the first detection adsorption layer 12, second respectively and third detection adsorption layer 14 sufficiently combines and is adsorbed on table
Layer；Finally, making it show and store in display device 5 under the action of acquisition equipment 4 and display device 5, convenient for after patient
Continuous examination；In entire use process, is sieved due to carrying out quantitative multicomponent label to diabetes, improves the stability of diagnosis,
Mistaken diagnosis is prevented, meanwhile, go out diabetes for Rapid&Early diagnosis and foundation is provided, convenient for the early treatment of patient.
The above embodiments are merely illustrative of the technical scheme of the present invention and are not intended to be limiting thereof, although referring to above-described embodiment pair
The present invention is described in detail, it should be understood by a person of ordinary skill in the art that still can be to of the invention specific
Embodiment is modified or replaced equivalently, and without departing from any modification of spirit and scope of the invention or equivalent replacement,
It is intended to be within the scope of the claims of the invention.
Claims (8)
1. a kind of multicomponent Labeled immunoassay system for diabetes, including detection pipeline (1) and electromagnet (2), special
Sign is: detection pipeline (1) left side up and down be respectively arranged with electromagnet (2), electromagnet (2) include upper electromagnet (21) and under
The left side central portion of electromagnet (22), detection pipeline (1) is provided with separating mechanism (11), and the left side of separating mechanism (11) is capture chamber
(101), the right side of separating mechanism (11) is sensing chamber (102), detects the lower inside on the right side of pipeline (1) from left to right successively
It is provided with the first detection adsorption layer (12), the second detection adsorption layer (13) and third detection adsorption layer (14), detection pipeline (1)
Lower right-hand side is provided with exciting bank (3), is detected and is provided with acquisition equipment (4) above the right side of pipeline (1), acquisition equipment (4)
It is connected by conducting wire with display device (5), the reagent (6) of detection diabetes autoantibody is provided in detection pipeline (1).
2. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1, it is characterised in that: every
Breaking mechanism (11) is inserted sheet.
3. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1, it is characterised in that: swash
Device (3) and acquisition equipment (4) are encouraged using photomultiplier tube.
4. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1, it is characterised in that: examination
There is the detection of the magnetic particle (7), biotinylation capture antigen (8), acridinium ester label of Streptavidin in agent (6) comprising coupling
Antigen (9) and substrate exciting liquid.
5. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1 or 4, feature exist
In: the first detection adsorption layer (12), the second detection adsorption layer (13) and third detection adsorption layer (14) are respectively used to capture strepto-
Magnetic particle (7), the biotinylation of Avidin capture the detection antigen (9) of antigen (8), acridinium ester label.
6. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1 or 4, feature exist
In: the partial size of the magnetic particle (7) of Streptavidin is 0.5-1.5 μm.
7. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1 or 4, feature exist
In: biotin captures antigen (8) and selects pancreatic island cell antigen albumen, and antigen protein concentration is 0.6 μ g/ml.
8. a kind of multicomponent Labeled immunoassay system for diabetes according to claim 1 or 4, feature exist
In: the detection antigen (9) of acridinium ester label selects acridinium ester label islet cell protein, and antigen protein concentration is 3 μ g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910606263.XA CN110244051A (en) | 2019-07-05 | 2019-07-05 | A kind of multicomponent Labeled immunoassay system for diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910606263.XA CN110244051A (en) | 2019-07-05 | 2019-07-05 | A kind of multicomponent Labeled immunoassay system for diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110244051A true CN110244051A (en) | 2019-09-17 |
Family
ID=67891257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910606263.XA Pending CN110244051A (en) | 2019-07-05 | 2019-07-05 | A kind of multicomponent Labeled immunoassay system for diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110244051A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0383129A2 (en) * | 1989-02-17 | 1990-08-22 | Bayer Corporation | Pancreatic islet cell antigens obtained by molecular cloning |
| CN101021529A (en) * | 2007-03-26 | 2007-08-22 | 南京大学 | High-flux detection system of multianalyte simultaneous detection and electrochemical immunoanalytical method |
| CN101539579A (en) * | 2009-04-28 | 2009-09-23 | 中国人民解放军第三军医大学第一附属医院 | Western blotting kit of diabetes mellitus autoantibody repertoire |
| US20090325190A1 (en) * | 2006-09-28 | 2009-12-31 | Cmed Technologies Ltd. | Method for quantitative detection of diabetes related immunological markers |
| CN103575880A (en) * | 2013-11-15 | 2014-02-12 | 司珂 | Multicomponent labeling immunoassay method and multicomponent POCT (Point-of-care testing) system |
| CN106771233A (en) * | 2016-12-05 | 2017-05-31 | 上海良润生物医药科技有限公司 | ZnT8A autoantibody detection kits |
| CN108414766A (en) * | 2018-01-29 | 2018-08-17 | 上海良润生物医药科技有限公司 | Kit for quantitatively detecting diabetes autoantibody and its application |
-
2019
- 2019-07-05 CN CN201910606263.XA patent/CN110244051A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0383129A2 (en) * | 1989-02-17 | 1990-08-22 | Bayer Corporation | Pancreatic islet cell antigens obtained by molecular cloning |
| US20090325190A1 (en) * | 2006-09-28 | 2009-12-31 | Cmed Technologies Ltd. | Method for quantitative detection of diabetes related immunological markers |
| CN101021529A (en) * | 2007-03-26 | 2007-08-22 | 南京大学 | High-flux detection system of multianalyte simultaneous detection and electrochemical immunoanalytical method |
| CN101539579A (en) * | 2009-04-28 | 2009-09-23 | 中国人民解放军第三军医大学第一附属医院 | Western blotting kit of diabetes mellitus autoantibody repertoire |
| CN103575880A (en) * | 2013-11-15 | 2014-02-12 | 司珂 | Multicomponent labeling immunoassay method and multicomponent POCT (Point-of-care testing) system |
| CN106771233A (en) * | 2016-12-05 | 2017-05-31 | 上海良润生物医药科技有限公司 | ZnT8A autoantibody detection kits |
| CN108414766A (en) * | 2018-01-29 | 2018-08-17 | 上海良润生物医药科技有限公司 | Kit for quantitatively detecting diabetes autoantibody and its application |
Non-Patent Citations (1)
| Title |
|---|
| 李涛等: "斑点金免疫渗滤法联合检测糖尿病自身抗体的研究", 《免疫学杂志》, vol. 30, no. 01, 1 January 2014 (2014-01-01), pages 70 - 74 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7901950B2 (en) | Method for assessing disease states by profile analysis of isolated circulating endothelial cells | |
| Gong et al. | High sensitive and multiple detection of acute myocardial infarction biomarkers based on a dual-readout immunochromatography test strip | |
| CN104650234B (en) | Anti- AKR1B10 protein monoclonal antibodies and its application | |
| CN108351358A (en) | Liver cancer test method | |
| CN101520458B (en) | Simple method for detecting HLA-G and antibody thereof by gold-labeled immunoassay | |
| CN105572353A (en) | Antibody chip reagent kit for detecting hepatoma marker | |
| US20210033605A1 (en) | Lateral flow immunoassay strip device | |
| CN104395755A (en) | Methods and compositions for personalized medicine by point-of-care devices for FSH, LH, HCG and BNP | |
| CN110456076A (en) | The method of multiple antibody immune magnetic beads enrichment detection CTCs | |
| Niu et al. | Time‐resolved fluorescent immunoassay‐based combined detection of procalcitonin, C‐reactive protein, heparin binding protein, and serum amyloid A1 to improve the diagnostic accuracy of early infection | |
| CN101086497A (en) | TORCH five-item combined detection card | |
| CN109187977A (en) | It is a kind of detect HER2 antigen different loci immunofluorescent reagent box and application | |
| CN206082559U (en) | A microfluid chip that outside being used for, secretes body separation, enrichment and detection | |
| CN206450690U (en) | A kind of circulating tumor cell detector | |
| CN106645756A (en) | Kit for detecting NMP22 (Nuclear Matrix Protein 22) and preparation method thereof | |
| CN102375057A (en) | Method for simultaneously detecting a plurality of serum markers by homogeneous fluorescence | |
| CN110244051A (en) | A kind of multicomponent Labeled immunoassay system for diabetes | |
| CN202583209U (en) | Optical excitation chemiluminiscence detection kit of pepsinogen I | |
| CN109932510B (en) | Cervical cancer biomarker and detection kit thereof | |
| CN203502418U (en) | Test device for quantitatively detecting soluble growth stimulation expression proteins 2 | |
| US20220187325A1 (en) | Assay device | |
| CN108535241A (en) | A kind of tachysynthesis detection device and its application | |
| CN102654499A (en) | Method for detecting optically-excited chemiluminiscence of pepsinogen 1 and reagent kit | |
| CN208350646U (en) | A kind of micro fluidic device and the detector comprising it, detection system | |
| WO2013003898A1 (en) | Method for detection of cancer in a patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |
|
| RJ01 | Rejection of invention patent application after publication |